VRX: Summary for Valeant Pharmaceuticals Interna - Yahoo Finance

Australia Markets close in 44 mins.

Valeant Pharmaceuticals International, Inc. (VRX)


NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
10.81+0.06 (+0.56%)
At close: 4:00PM EDT
People also watch
AGNGILDFITENDPBIIB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close10.75
Open10.69
Bid0.00 x
Ask0.00 x
Day's range10.66 - 10.94
52-week range10.35 - 38.50
Volume8,982,106
Avg. volume18,763,103
Market cap3.76B
Beta-1.07
PE ratio (TTM)-1.56
EPS (TTM)N/A
Earnings dateN/A
Dividend & yield0.00 (0.00%)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • AFP14 days ago

    Valeant shares plunge as Ackman exits stake

    Shares of Valeant Pharmaceuticals International plunged Tuesday following news that activist investor Bill Ackman exited the controversial drug company. Shares of the Canadian company dived 10.9 percent to $10.80 by midday after an announcement that Ackman's hedge fund, Pershing Square Capital Management, sold its investment in the drug firm at a loss. In addition, Ackman and fellow Pershing executive Stephen Fraidin said they would step down from the Valeant board.

  • ABN Newswire2 months ago

    Jaguar Animal Health, Inc. (NAS:JAGX) Given Company Update by Aegis Capital Corp.

    New York, United States, Jan 11, 2017 - (ABN Newswire) - (NetworkNewsWire) Jaguar Animal Health, Inc. (NAS:JAGX - News), a company in the business of developing and commercializing gastrointestinal products for companion animals, horses, and production animals, recently had its company outlook updated by Aegis Capital Corp. (http://nnw.fm/8Jn4H). The company update was announced after JAGX made several decisions that Aegis believes could improve the outlook for the company. The company, which is committed to identifying animal health market opportunities to develop products specific to various species, announced that it has proposed a business combination with its parent company, Napo Therapeutics, Inc., to form a single entity.

  • noodls3 months ago

    Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors

    LAVAL, Quebec, Jan. 4, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ('Valeant') today announced that the Board of Directors has elected Richard (Dick) U. DeSchutter ...